Regulations
The medical device market and United Kingdom requires understanding that UK devices fall under the regulation of the UK Medical Device Regulations 2002 which the UK MHRA enforces under the consumer protection act 1987. EU MDR and EU IVDR do not apply in GB it is closely aligned to the old requirements the deadlines for transition for older directive devices are June 38, 2028 and for the updated rules an additional deadline for two years of 2030 has been provided however when selling in northern Ireland the European regulations apply directly under the Windsor framework. To get into Great Britain the UK MHRA lets you use UKCA or transitional CE marks but for Northern Ireland you must have a valid CE mark or a combined CE UK(NI) mark if using a UK body. Overseas like US FDA approvals are not recognized at all by the UK MHRA so you have to pass the proper conformity routes anyway to get your product.
If you are a manufacturer based outside the UK you have to appoint a single representative before selling anything. For Great Britain you must get a UK Responsible Person who is physically based there to handle the UK MHRA. This person has to check your declaration of conformity and technical docs to make sure they are drawn up right and keep copies ready for when the UK MHRA wants to inspect them. They also pass on any sample or data requests from the regulator and they must terminate the contract if the manufacturer breaks the law. For Northern Ireland you are treated as a third party so you have to get an Authorized Representative based in the EU or NI instead. Also for account logistics on the system the old representative accounts that did not switch over were suspended back in 2022. If you do not update this by the final deadline of March 30 2026 the UK MHRA will permanently close the account and you will have to make a new one from the beginning.
Device Classification and MHRA Medical Device Registration
Your product has to fit the definition of a medical device or diagnostic and then it gets classified by risk so the UK MHRA can control it. General devices go from Class I up to Class IIa Class IIb and Class III while active implantables have higher risk rules and IVDs are split into general, Annex II List A, Annex II List B, or self test. Low risk non sterile Class I items and general diagnostics can be self certified by the manufacturer. Higher classes need a third party like a UK Approved Body for Great Britain or an EU Notified Body for Northern Ireland. For high risk diagnostics the approved bodies must check the products on a strict batch by batch basis. Your physical labels must show the UKCA or CE mark with the body number. If you use the UKCA route you must put the UKRP name and address on the label or packaging but you do not need this for pure CE marked transition items.
Registration Portals and UK Medical Device Registration Fees
Everything from devices and diagnostics to custom packs must be registered with the UK MHRA before you can sell them. This mandatory MHRA Medical Device Registration process under section 7d costs a flat fee of £300 for every Level 2 GMDN category or Level 1 if Level 2 is not there. For Northern Ireland you have to register as an actor on the European EUDAMED database with your EORI number and trade register info. The modules for actors, devices, notified bodies and market surveillance became mandatory on May 28 2026 while the post market and clinical modules became mandatory as soon as they dropped without any voluntary phase. Distributors do not have to register as actors on EUDAMED. Custom made devices for NI bypass EUDAMED and go on the domestic DORS system within 28 days of making them available. If an NI manufacturer already registered with the UK MHRA for the local market they can sell in Great Britain with no extra registration or fees.
Clinical Investigation Pathways and UK Medical Device Registration Costs
If you want to run clinical trials in the UK for general or active implantable devices you have to notify the UK MHRA at least 60 days before starting. This 60 day notice does not apply to diagnostics but you still have to tell them about performance evaluations. The application fees are tiered under section 7a based on device risk. For Class I, IIa, and non high risk IIb devices the initial fee is £15,309 and resubmissions cost £11,701. For high risk Class IIb, Class III, and active implantables the initial fee is £32,016 and resubmitting costs £22,678. To avoid losing your money you can book pre submission paths like a statistical review for £852 or a regulatory advice meeting for £987.
Special Rules for Combination Products
Complex device combination products with medicinal substances have special consultation fees under section 8 depending on where the medicine comes from. If it is a known substance from an approved source the fee is £4,953 with £980 follow ups. A known substance from a new source costs £11,543 with £2,668 follow ups and a completely new active substance costs £50,644 with £12,574 follow ups. These follow a multi substance rule so if there are two or more medicines the whole fee defaults to the highest price tier but the price stays the same regardless of the dose concentration. You can group similar devices using the exact same medicine under a single fee if you apply at the same time. For bodies extending their scope for these combination products an assessment by the Secretary of State costs £19,824 while extensions for already designated sections cost £13,684 and subsidiary audits cost £24,806 plus travel.
International Recognition and Parallel Imports
If you have multiple product lines using international recognition or parallel import pathways the fees under sections 14 and 16 are:
Major International Recognition Type B: £83,580
Major International Recognition Type A: £24,688
Abridged Complex International Recognition Type B: £23,205
Abridged Complex International Recognition Type A: £13,983
Standard International Recognition Type B: £8,503
Standard International Recognition Type A: £7,743
Parallel imports for cross border device medicinal products cost £2,400 for simple apps, £10,617 for standard apps, and £24,343 for complex ones where there is no common origin between the import and the UK reference product.
Technical Validation and Approved Body Audits
For overseas companies needing third party evaluation the system has detailed fees for Approved Bodies under section 7b:
Initial designation applications: £41,337
Initial designation audit fee: £67,606
Ongoing surveillance audits: £52,929
Witnessed audits: £11,672
Follow up audit for a major closure: £26,408
Special clinical follow up audit: £21,535
Process specific or subsidiary audits: £26,408
TSE application assessment fee: £1,503 for devices using materials sensitive to TSE
Scope extensions: £21,105 for a new code or £14,568 if codes are limited
Any standard physical or paperwork auditing outside the fixed scope is billed at a daily operational rate of £1,463.
UK Medical Device Regulations and the International Recognition Procedure
The UK’s International Recognition Procedure (IRP) requires careful planning if your medicinal product relies on an integral device or requires an external diagnostic. Under the statutory UK Medical Device Regulations, the preparation of these device components mandate your entire submission timeline. Failing to meet specific conformity standards will automatically disqualify your application from the expedited 60-day Route A and push it into the 110-day Route B pathway.
The Three Triggers for Route B
Your application will face this 50-day delay under three conditions:
Missing Marks: Co-packaged medical device components lack a valid CE or UKCA mark.
Uncertified Diagnostics: A required In Vitro Diagnostic (IVD) lacks proper certification.
No Evaluation Report: You cannot provide an official evaluation report from an approved or notified body for integral components.
Importer Obligations for Northern Ireland
When overseas devices enter Northern Ireland the local importer has to check everything under Article 13 of the MDR and IVDR. They must technically verify that the device has a CE mark, the declaration of conformity is drawn up, the manufacturer is identified, a representative is appointed, and a UDI is assigned. Importers have to put their own name and address details on the device packaging or invoice and they must keep copies of the conformity certificates for at least 10 years or 15 years if it is an implantable product.
Post Market Surveillance Dynamics and MHRA Medical Device Registration Mandates
Manufacturers have to send detailed vigilance reports to the UK MHRA when bad incidents happen in the UK and do field safety fixes quickly. In Great Britain the rules for post market surveillance were tightened by laws that came into full force on June 16 2025 to track incidents better. For Northern Ireland you report incidents through the MORE system while local doctors use the Yellow Card portal. Under Article 10a if you expect a supply interruption or discontinuation that could hurt public health you must tell the UK MHRA and your buyers at least 6 months in advance. There is an exemption saying interruptions expected before January 10 2025 do not need to be reported even if the actual physical supply stop happens after that date.
Extended CE Transitional Timelines and the UK Medical Device Regulations
If you are using an EU CE mark instead of a UKCA mark the UK government has extended timelines for entering Great Britain under the frameworks outlined by the UK Medical Device Regulations.
Old EU MDD or AIMDD devices: allowed until the certificate expires or June 38, 2028 whichever comes first (includes Class I sterile or measuring items)
Old EU IVDD diagnostics: allowed until the certificate expires or June 30, 2030
New EU MDR or IVDR devices: full access in Great Britain until June 30, 2030
For self declared CE devices with no notified body general devices under old directives are allowed if the declaration was done before May 26 2021 and is still valid under EU transitions. Self declared diagnostics are allowed if done before May 26 2022. Class I devices self declared under modern EU rules are valid until June 30, 2030. Class I devices that got classified under newer rules like reusable surgical tools that now need a notified body are extended until June 30, 2028 if they were self declared before May 26 2021. Extended certificates under EU law can be used to register and sell devices in both Great Britain and Northern Ireland until their revised transition dates.
Getting a Certificate of Free Sale for medical devices costs £75 for the first 10 certificates and £10 for every extra certificate on the same order. For Northern Ireland the local fees for designating and monitoring notified bodies or getting free sale certificates stay at the same level as current fees. If you want to dispute a final decision made by the licensing authority regarding your device or combination app you can start a formal appeal for a Review Panel Hearing under the human medicines regulations 2012 for an upfront fee of £11,974. The refund rules say:
You get a 100% refund if you win and the decision is turned over
You get a 60% partial refund if you withdraw before the panel is formally appointed
You get a 0% refund and lose all your money if you withdraw after the panel is appointed.
What are the exact upfront application fees and remediation costs if an overseas manufacturer must run a local clinical investigation in the UK?
The fees are tiered by the risk profile of the device under section 7a if you need to run clinical trials in the UK. For Class I, IIa, and non-high-risk IIb devices the initial fee is £15,309 and if you need remediation the resubmission fee is £11,701. For high-risk Class IIb, Class III, and active implantable devices the upfront initial fee is £32,016 and if formal remediation and resubmission are needed the fee is £22,678.
What are the specific timelines and rules regarding supply discontinuations or interruptions that could cause public health harm in Northern Ireland?
If you expect a supply interruption or discontinuation that could cause serious public health harm you must tell the UK MHRA and your buyers at least 6 months in advance. There is a temporary exemption saying any interruptions expected before January 10 2025 do not have to be reported even if the actual physical supply drop happens after that date.
What are the primary administrative barriers to entry regarding historical representative accounts on the registry system, and what is the final hard deadline for compliance?
Old representative accounts that failed to switch over to a UK Responsible Person on the registration system were suspended on January 1 2022 along with their manufacturers' accounts. If you do not update this role switch by the hard deadline of March 30 2026 the registry will permanently close the account and you will have to make an entirely new one from scratch.
If our device is a drug-device combination product, how do the characteristics or number of medicinal substances alter the statutory consultation fees?
The system has two specific rules for combination products under section 8. Under the multi-substance rule if a device has two or more medicinal substances the whole fee defaults to the tier of the higher priced substance. Under concentration invariance the statutory fee stays exactly the same regardless of the therapeutic strength, dose, or concentration levels of the medicine used.
What are the financial costs billed to third-party validation entities for undergoing initial designation, surveillance, and localized site audits by regulatory auditors?
The metrics for Approved Body fees under section 7b are £41,337 for the initial designation application and £67,606 for the initial designation audit. Ongoing surveillance audits cost £52,929, witnessed audits cost £11,672, and a follow up audit for a major closure costs £26,408. A special clinical follow up audit or a process specific audit costs £26,408 while standard auditing outside fixed scopes is billed at a daily operational rate of £1,463.
What are the specific document verification, labeling, and storage duration mandates imposed on local importers bringing overseas devices into Northern Ireland?
Under Article 13 the local importer must verify that the device is CE marked, the declaration of conformity is done, the manufacturer is identified, a representative is appointed, and a UDI is assigned. Importers must put their own name and address details on the device packaging or invoice and they must keep copies of the declaration of conformity and certificates for at least 10 years or 15 years if it is an implantable product.
If an overseas manufacturer disputes a licensing or combination application decision, what is the cost of an appeal and how do withdrawal timelines affect refunds?
You can start a formal appeal for a Review Panel Hearing under the human medicines regulations 2012 for an upfront fee of £11,974. The refund rules say you get a 100% refund if you win the appeal and the original decision is turned over. You get a 60% partial refund if you withdraw the appeal before the specific panel is formally appointed but you get a 0% refund and the whole fee is lost if you withdraw after the panel has been officially appointed.
How does the UK Medical Device Regulations framework define the baseline protocol for localized data tracking, and what are the primary administrative steps to complete an initial MHRA Medical Device Registration or a separate UK Medical Device Registration for global product distribution lines?
The overarching tracking protocols are governed entirely under the core UK Medical Device Regulations framework which dictates localized compliance. For standard market placement, completing your primary MHRA Medical Device Registration requires submission via the online portal alongside the necessary GMDN coding details. If your business infrastructure handles distinct product divisions, a secondary UK Medical Device Registration must be finalized separately for each designated entity to avoid administrative processing delays with the MHRA.